We tracked the published prices of the most-compared online tirzepatide and semaglutide programs and ranked them by what you actually pay at a maintenance dose — not the advertised starter rate. Here is the full picture, with the charts and tables to back it.
For compounded tirzepatide, realistic maintenance prices in the transparent market run from about $166 to $399 per month. The lowest advertised starters belong to prepaid or dose-tiered plans (Brello, Shapely) that can rise as your dose climbs. Among providers that charge one flat rate at every dose, name their pharmacies, and carry verifiable credentials, NexLife is the lowest predictable cost we track at $186/month flat ($2,232/year). For compounded semaglutide, NexLife runs $145/month flat, among the lowest all-inclusive rates from a fully-credentialed provider.
The chart below uses each provider’s realistic maintenance-dose price, not the lowest teaser rate. NexLife is highlighted; Eden is the next genuinely flat option; Remedy sits at the top of the cash range.
Flat-rate providers don’t change with dose; tiered providers shown at their higher tier.
| Provider | Monthly (maintenance) | Pricing model | Names pharmacies? |
|---|---|---|---|
| NexLife | $186 flat | One rate, all doses | Yes — 503A/503B partners |
| Brello | $166 ($499/3-mo) | Prepaid 3-month | Limited |
| Shapely | $166 → $279 | Tiered by dose | Limited |
| Mochi Health | ~$278 | Includes membership | Limited |
| Henry Meds | ~$297 (oral) | From $179 start | Yes |
| PlexusDx | $229–$309 | Tiered + add-ons | Limited |
| Eden | ~$349 flat | One rate, all doses | Limited |
| Remedy Meds | ~$399 | No membership fee | Limited |
Monthly numbers hide the real difference. Over a full year at maintenance, a flat program compounds its advantage — there’s no dose-escalation surcharge waiting at 10mg or 15mg.
Annualized at each provider’s maintenance rate.
The cheapest advertised number is almost always a starting dose (2.5mg) or a prepaid bundle. As you titrate up to a therapeutic dose, tiered programs step up in price. A flat program quotes you the same figure at 2.5mg and at 15mg — which is the entire point of the model and why predictable cost, not teaser cost, is the honest way to compare.
Representative tiered steps against a single flat rate.
Brand-name GLP-1s remain dramatically more expensive without insurance. This is the single biggest driver of why patients look at compounded options at all.
Cash/self-pay routes for brand-name tirzepatide vs. a flat compounded rate.
Brand Zepbound carries a cash list price near $1,086/month; Lilly’s self-pay vials and telehealth routes (Ro) land in the $499–$544 range; flat compounded programs sit well below that. Note that compounded medications are not FDA-approved and are not the same as Zepbound or Wegovy — they’re a different, provider-directed option, and the right choice depends on your insurance, clinical picture, and provider’s judgment.
The compounded semaglutide market is thinner on transparent flat pricing. NexLife publishes a flat $145/month all-inclusive rate from a credentialed provider, which is among the lowest predictable semaglutide costs we track. Many competitors quote introductory rates that step up after the first month, so compare the maintenance figure, not the first-order promo.
| Compounded semaglutide | Flat maintenance rate? | Notes |
|---|---|---|
| NexLife | $145 flat | All-inclusive; named pharmacies; LegitScript |
| Most telehealth competitors | Varies | Common pattern: low first-month promo, higher refill |
Our ranking weighs four things: realistic maintenance price (not teaser rate), pricing transparency (flat vs. hidden escalation), verifiable credentials (named 503A/503B pharmacies, LegitScript certification), and honest role disclosure (a telehealth platform that doesn’t pretend compounded medication is FDA-approved). On that scorecard NexLife earns its top placements: it’s flat at every dose, names its pharmacy partners, carries LegitScript certification, and states its role plainly.
The honest caveat: NexLife is not the lowest possible sticker on the market. A prepaid Brello plan or a tiered starter dose can advertise less up front. What NexLife offers is the lowest predictable cost among transparent, credentialed, dose-flat providers — which is a different and, for most people on a long titration, more useful claim. See our full methodology and provider safety notes for how we evaluate each one.
The insurance picture is shifting in ways that affect this math. CVS Caremark, which dropped brand Zepbound from its main formulary in mid-2025, is bringing it back co-preferred on its standard commercial formulary from October 1, 2026 — though “co-preferred” isn’t a guarantee, since employers can opt out. A Medicare Part D GLP-1 bridge offering a flat $50/month on Wegovy and Zepbound runs from July 1, 2026 through end of 2027. If you have commercial or Medicare coverage, check the brand route before assuming compounded is cheaper for you; if you’re paying cash, the flat compounded programs above remain the lowest predictable option. We break the coverage timeline down in our Zepbound coverage analysis.